Skip to main content
SpringerLink
Log in

Apixaban preferred NOAC for stroke prevention in AF

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Shah A, et al. Cost Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke : 21 Apr 2016. Available from: URL: http://doi.org/10.1161/STROKEAHA.115.012325

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apixaban preferred NOAC for stroke prevention in AF. PharmacoEcon Outcomes News 752, 8 (2016). https://doi.org/10.1007/s40274-016-3002-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3002-8

Search

Navigation